

YOUR PATIENTS MAY QUALIFY FOR A CLINICAL TRIAL AT UNC

**UNC Lineberger Comprehensive Cancer Center Seeks Patients for Clinical Trial
Evaluating CAR-Macrophage Therapy for HER2-Overexpressing Solid Tumors**

CARISMATX.COM

The University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger) is conducting a clinical trial of an experimental therapy for metastatic HER2-overexpressing solid tumors. As a health care provider, you have the opportunity to contribute to scientific discovery by referring patients who may be eligible for this trial.

THE FIRST CAR-ENGINEERED MACROPHAGE (CAR-M) CELL THERAPY CLINICAL TRIAL

Chimeric antigen receptor (CAR) T cell therapy has unlocked new possibilities in the fight against some of the most difficult-to-treat hematological cancers. However, solid tumors have been resistant to this advanced form of immunotherapy.

CARISMA Therapeutics has partnered with UNC Lineberger to evaluate its autologous, anti-HER2 CAR-M therapy, CT-0508. Preclinical findings suggest that CAR-Ms trigger a combined innate and adaptive, long-lasting immune response, potentially increasing overall survival. This is a first in human trial of this novel therapy. The main objective is safety and tolerability. UNC Lineberger's researchers will track objective response rates to the treatment and estimate progression-free survival as secondary outcomes.

YOUR PATIENT MAY BE A FIT FOR THIS CLINICAL TRIAL IF HE/SHE MEETS ALL THREE OF THE FOLLOWING CRITERIA*:

- Locally advanced or metastatic cancer of any origin, including but not limited to breast, gastric, gastroesophageal junction, lung, bladder, pancreatic, biliary, ovarian, and others.
- HER2-positive tumor, and inoperable/incurable.
- Received approved therapies and is either not tolerating or is progressing.

***IF YOU HAVE A PATIENT WITH AN UNKNOWN HER2 EXPRESSION STATUS, ARCHIVAL TISSUE CAN BE USED TO PRESERVE PATIENTS FOR THIS STUDY.**

As you know, advancing medicine through clinical research relies on the participation of patient volunteers. We urge you to discuss this opportunity with anyone who meets the above criteria. Please refer all interested patients to Catherine Cheng, UNC Lineberger's Lead Study Coordinator at unccart@unchealth.unc.edu.

We appreciate your commitment to clinical research.